Viralgen and Elaaj Bio announce a partnership aimed at developing a gene therapy for the rare pediatric condition known as CDKL5 deficiency. Their work is crucial for accelerating clinical development.

Viralgen collaborates with Elaaj Bio to enhance a gene therapy program for CDKL5 deficiency disorder, a rare neurological condition affecting children.

UCB has revealed promising findings from the GEMZ phase 3 trial, demonstrating that fenfluramine significantly lessens seizure frequency in patients with CDKL5 deficiency disorder.

UCB revealed promising results from its GEMZ Phase 3 study, showing fenfluramine effectively reduces seizure frequency in patients with CDKL5 Deficiency Disorder.